¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"acute lymphoblastic leukemia, null cell type"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
  • germ cell
    Á¾ÀÚ¼¼Æ÷, »ý½Ä¼¼Æ÷, ¹è¼¼Æ÷
  • germinal cell
    Á¾ÀÚ¼¼Æ÷
  • ghost cell
    À¯·É¼¼Æ÷
  • ghost cell glaucoma
    ºó¼¼Æ÷³ì³»Àå, À¯·É¼¼Æ÷³ì³»Àå
  • giant cell
    °Å´ë¼¼Æ÷
  • giant cell carcinoma
    °Å´ë¼¼Æ÷¾ÏÁ¾
  • giant cell epulis
    °Å´ë¼¼Æ÷Ä¡ÀºÁ¾
  • giant cell glioblastoma
    °Å´ë¼¼Æ÷¾Æ±³¸ð¼¼Æ÷Á¾, °Å´ë¼¼Æ÷±³¸ð¼¼Æ÷Á¾
  • giant cell granuloma
    °Å´ë¼¼Æ÷À°¾ÆÁ¾
  • giant cell myeloma
    °Å´ë¼¼Æ÷°ñ¼öÁ¾
  • giant cell myocarditis
    °Å´ë¼¼Æ÷½É±Ù¿°
  • giant cell pneumonia
    °Å´ë¼¼Æ÷Æó·Å
  • giant cell tumor
    °Å´ë¼¼Æ÷Á¾¾ç
  • glandular cell
    »ù¼¼Æ÷, ¼±¼¼Æ÷
  • glial cell
    ½Å°æ¾Æ±³¼¼Æ÷
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
  • granulosa cell carcinoma
    °ú¸³¼¼Æ÷¾ÏÁ¾
  • hair cell
    Åм¼Æ÷
  • hairy cell
    Åиð¾ç¼¼Æ÷
  • HeLa cell
    Çï¶ó¼¼Æ÷
  • helmet cell
    Åõ±¸¼¼Æ÷
  • helper cell
    µµ¿ò¼¼Æ÷, Á¶·Â¼¼Æ÷
  • hemolytic plaque-forming cell
    ¿ëÇ÷ÆÇÇü¼º¼¼Æ÷, ¿ëÇ÷ÇöóÅ©Çü¼º¼¼Æ÷
  • heterotrophic cell
    Á¾¼Ó¿µ¾ç¼¼Æ÷
  • high-threshold cell
    °í¹®Åΰª¼¼Æ÷
  • horizontal cell
    ¼öÆò¼¼Æ÷
  • horny cell
    °¢Áú¼¼Æ÷
  • hybrid cell
    ÀâÁ¾¼¼Æ÷
  • hypersensitized cell
    °ú¹Î°¨¼¼Æ÷
  • immunologically competent cell
    (¢¡immunocyte) ¸é¿ª¼¼Æ÷
  • indeterminate cell
    ºÎÁ¤Çü¼¼Æ÷
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
  • acute pulpitis
    ±Þ¼º Ä¡¼ö¿°(¡­öÍâÐæú).
  • acute purulent otitis media
    ±Þ¼º È­³ó(¼º) ÁßÀÌ¿°
  • acute purulent pulpitis =a. suppurative p.
    ±Þ¼º È­³ó¼º Ä¡¼ö¿°(¡­ûùÒÛàõöÍâÐæú).
  • acute pyelonephritis
    ±Þ¼º ½Å¿ì½Å¿°(¡­ãì ãìæú).
  • acute radiation dermatitis
    ±Þ¼º ¹æ»ç¼± ÇǺο°
  • acute radiation sickness
    ±Þ¼º¹æ»ç¼±Áõ
  • acute radiation syndrome
    ±Þ¼º¹æ»ç¼±ÁõÈıº
  • acute radiation syndrome
    ±Þ¼º¹æ»ç¼±ÁõÈıº(¡­Û¯ÞÒàÊñøý¦ÏØ)
  • acute renal failure
    ±Þ¼º ½ÅºÎÀü(Áõ)(¡­ãìÝÕîïñø).
  • acute respiratory disease =ARD
    ±Þ¼º È£Èí±âº´(¡­û¼ýåÐïÜ»).
  • acute respiratory disease =ARD
    ±Þ¼º È£Èí±âº´(¡­û¼ýåÐïÜ»).
  • acute respiratory illness =ARI
    ±Þ¼º È£Èí±âº´.
  • acute respiratory illness =ARI
    ±Þ¼º È£Èí±âº´.
  • acute retinal necrosis
    ±Þ¼º¸Á¸·±«»ç
  • acute rheumatic arthritis
    ±Þ¼º·ù¸¶Æ¼½º¼º °üÀý¿°
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
  • platelet-type
    Ç÷¼ÒÆÇÇü(û¡)
  • pneumocyte type i
    È£ÈíÇãÆÄ²Ê¸®¼¼Æ÷
  • pneumocyte type ii
    °ú¸³ÇãÆÄ²Ê¸®¼¼Æ÷
  • precision type attachment
    Á¤¹ÐÇü¾îÅÂÄ¡ ¸ÕÆ®.
  • propagative type
    Áõ½ÄÇü(Ì¡ËàÌ´).
  • protease inhibitor type
  • pseudorabies virus (Suid herpesvirus type 1)
    ½´µµ·¹À̺ñ½º¹ÙÀÌ·¯½º (Á¦1Çü µÅÁö Ç츣Æä½º¹ÙÀÌ·¯½º, ¿¾ Herpesvirus suis)
  • pyknic body type
    ºñ¸¸Çü ½ÅüÀ¯Çü
  • regular type
    ±ÔÄ¢Çü
  • repository type of penicillin
    ÀúÀåÇü(îÍíúû¡) Æä´Ï½Ç¸°.
  • saddle type pontic
    ¾È»ó°¡°øÄ¡(äÓßÒ Ê­ÍïöÍ).
  • schizophrenia of residual type
    ÀÜ·ùÇü Á¤½ÅºÐ¿­º´(íÑë§úþïñãêÝÂæññø).
  • schizophrenia, disorganized type
    ºØ±«Çü Á¤½ÅºÐ¿­º´
  • schizophrenia, hebephrenic type
    ÆÄ°úÇü Á¤½ÅºÐ¿­º´
  • schizophrenia, paranoid type
    ÆíÁýÇü Àü½ÅºÐ¿­º´
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 19
SCC self-care center; sequential combination chemotherapy; services for crippled children; short-course ...
SCM Schwann cell membrane; sensation, circulation, and motion; Society of Computer Medicine; soluble cyt...
TCE T-cell enriched; tetrachlorodiphenyl ethane; trichloroethylene T-cell thymus-derived cell
TCR T-cell reactivity; T-cell receptor; T-cell rosette; thalamocortical relay; total cytoplasmic ribosom...
WBC well baby care/clinic; white blood cell; white blood cell count; whole blood cell count
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 19
LAK cell lymphokine activated killer cell
M cell Mauthner cell
NK cell natural killer cell
P-cell Purkinje cell
TCRBCL T cell rich B cell lymphoma
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • blood cell counter
    Ç÷±¸ °è¼ö±â
  • bone cell
    °ñ ¼¼Æ÷
    °ñÁ¶Á÷ÀÇ ±âº» ¼¼Æ÷. °ñ Á¶Á÷¿¡´Â µüµüÇÑ °ñ ±âÁú¾È¿¡ °ñ¼Ò°­À̶ó°í ÇÏ´Â Æ´ÀÌ ±ºµ¥±ºµ¥ ÀÖ°í, ±× ¼Ó¿¡ 1°³¾¿ÀÇ °ñ ¼¼Æ÷°¡ µé¾î ÀÖ´Ù. °ñ ¼¼Æ÷ÀÇ ÇüÅ´ °ñ¼Ò°­°ú ÀÏÄ¡ÇÏ¿© ÆíÆòÇÑ Å¸¿øÇüÀ¸·Î, ±æÀÌ´Â 15¡­27 ¥ìmÀÌ´Ù. °ñ ¼¼Æ÷´Â ´Ù¼öÀÇ °¡´Â ¿øÇüÁú µ¹±â°¡ À־, À̰ÍÀÌ ±âÁú ³»ÀÇ °ñ ¼¼°üÀ» ÅëÇÏ¿© °¡±îÀÌ ÀÖ´Â °ñ ¼¼Æ÷ÀÇ µ¹±â¿Í ÇÕÄ£´Ù. °ñ ¼¼Æ÷´Â º»·¡ °áÇÕÁ¶Á÷ÀÇ ¼¶À¯¾Æ¼¼Æ÷¿¡¼­ Çü¼ºµÇ´Â °ÍÀ¸·Î, ¸ÕÀú °ñ¾Æ¼¼Æ÷°¡ µÇ¾î, À̰ÍÀÌ ±âÁúÀ» ¸¸µé°í ÀÚ½ÅÀº ±× ±âÁú ¼Ó¿¡ µé¾î°¡ °ñ¼¼Æ÷·Î µÈ´Ù. À̰ÍÀº °ñ Á¶Á÷ÀÇ Á¦Á¶ÀÚÀ̸ç, ¼¼Æ÷ÁúÀº ¹Ì·®ÀÇ ¹ÌÅäÄܵ帮¾Æ¸¦ Æ÷ÇÔÇϰí, È£¾à¿°±â¼ºÀ» ³ªÅ¸³½´Ù.
  • bone marrow cell
    °ñ¼ö ¼¼Æ÷
  • bristle cell
    °­¸ð ¼¼Æ÷, ¸ð¼¼Æ÷
  • calcigerous cell
    ¼®È¸È­ ¼¼Æ÷
  • cameloid cell
    Ÿ¿øÇü ÀûÇ÷±¸
  • cancer cell
    ¾Ï ¼¼Æ÷
    Á¤»óÀÎ Á¶Á÷ ¼¼Æ÷°¡ ¾î¶² ¿øÀÎÀ¸·Î ¹«Á¦ÇÑ Áõ½ÄÇÏ¿© ±× »ýüÀÇ »ýȰÇö»óÀ̳ª ÁÖÀ§ÀÇ Á¶Á÷ »óÅ µî¿¡ °ü°è¾øÀÌ ±Þ¼ÓÇÑ ¹ßÀ°À» °è¼ÓÇÏ¿© ¸¶Ä§³»´Â »ý¸íÀ» ²÷°Ô ÇÏ´Â ¾Ç¼ºÀÇ ½Å»ý¹°À̶ó°íµµ º¼ ¼ö ÀÖ´Â ¼¼Æ÷. ¼¼Æ÷ÇÐÀûÀ¸·Î º¸¸é ±× ¸ð¾çÀ̳ª Å©±â°¡ Á¤»ó ¼¼Æ÷¿¡ ºñÇÏ¿© ´Ù¼Ò º¯È­µÇ¾î ÀÖ´Ù. Áï, ÇÙÀº ¿°»öü°¡ ¸¹°í, ÇÙÀÇ ¿øÇüÁú¿¡ ´ëÇÑ ºñ°¡ Å©¸ç, ÇÙ¼Òü¸¦ °¡Áö°í, ÀÚÁÖ ÇÙ ºÐ¿­»óÀ» ³ªÅ¸³½´Ù. À̰ÍÀ» ÀÌÇü¼ºÀ̶ó°í ÇÑ´Ù. ÀÌÇü¼ºÀÌ °­ÇÑ °ÍÀÌ ¾Ï ¼¼Æ÷ÀÇ Æ¯Â¡ÀÌ´Ù. À̰ÍÀ» ÀÌ¿ëÇÑ °ÍÀÌ ¼¼Æ÷ÁøÀ̸ç, À§¾Ï µî ¸ðµç ¾ÏÀÇ Á¶±â Áø´Ü¿¡ Å« ¿ªÇÒÀ» Çϰí ÀÖ´Ù. Á¤»ó ¼¼Æ÷°¡ ¾î¶»°Ô ÇØ¼­ ¾Ï ¼¼Æ÷·Î º¯Çϴ°¡´Â ºÒ¸í·áÇÑ Á¡ÀÌ ¸¹Áö¸¸, È÷¸£È¿ÀÇ Àڱؼ³Àº À¯¸íÇÏ´Ù. À̰ÍÀº È­ÇÐÀû, ±â°èÀû, ¹°¸®Àû µîÀÇ ¸¸¼º ÀÚ±ØÀÌ ÀÛ¿ëÇÏ´Â °÷¿¡ ¾ÏÀÌ ¹ß»ýÇÑ´Ù´Â ¼³ÀÌ´Ù. ¹ÙÀÌ·¯½º¿ÍÀÇ °ü°èµµ ±Ù³â¿¡ ÁÖ¸ñÀ» ²ø¾î, F.P. ¶ó¿ì½ºÀÇ ´ßÀÇ À°Á¾ ¹ÙÀÌ·¯½º³ª R.E. ¼îÇÁÀÇ Åä³¢ÀÇ À¯µÎÁ¾ ¹ÙÀÌ·¯½º´Â À¯¸íÇÏÁö¸¸, Àΰ£ÀÇ ¾Ï°ú È®½ÇÇÏ°Ô °ü°è¸¦ °®´Â ¹ÙÀÌ·¯½º´Â ¾ÆÁ÷ ¹ß°ßÇÏÁö ¸øÇϰí ÀÖ´Ù. ¾Ï ¼¼Æ÷°¡ Á¤»ó ¼¼Æ÷¿Í ´Ù¸¥ Á¡Àº ÀÚÀ²ÀûÀ¸·Î Áõ½ÄÇϰí ÁÖÀ§ÀÇ Á¶Á÷À» ÆÄ±«ÇÏ¿© ħÀ±¼ºÀ¸·Î ¹ßÀ°ÇÏ´Â °Í, ¾Ï ¼¼Æ÷°¡ À¯¸®µÇ¾î ¸²ÇÁÇ༺, Ç÷Ç༺À¸·Î ¿ø°Ý Àå±â¿¡ ÀüÀÌÇÏ´Â °Í, ÆÄÁ¾À̶ó ÇÏ¿© º¹°­³»³ª Èä°­³»ÀÇ Àå±âÀÇ ¾Ï¿¡¼­´Â ¾Ï ¼¼Æ÷°¡ À帷¿¡ µµ´ÞÇÏ¸é º¹¸·À̳ª È丷¿¡ ºÎÂøÇÏ¿© ¹ßÀ°À» °è¼ÓÇÏ´Â °Í µîÀÌ´Ù. ÀÌ·± Ư¼º ¶§¹®¿¡ ¾ÏÀÇ Ä¡·á°¡ º¹ÀâÇØÁö°í Àç¹ßµÇ±â ½±´Ù. µû¶ó¼­ ¾ÏÀ» °íÄ¡·Á¸é ¾Ï ¼¼Æ÷°¡ ÀÌ·± Ư¼ºÀ» ÃæºÐÈ÷ ¹ßÈÖÇÏÁö ¸øÇÏ´Â Á¶±â¿¡ ¹ß°ß, Ä¡·áÇØ¾ß ÇÑ´Ù.
  • capsule cell
    ÇǸ· ¼¼Æ÷, À§¼º ¼¼Æ÷
  • caterpillar cell
    ¸ðÃæ ¼¼Æ÷
  • caveolated cell
    ¼ÒÆ÷¿ò ¼¼Æ÷
    ÈçÈ÷ º¼ ¼ö ÀÖ´Â °ÍÀº ¾Æ´ÏÁö¸¸, ¼ÒÀå, ´ëÀå, À§ µîÀÇ ¿ò°ú À¶¸ð¿¡¼­ º¼ ¼ö ÀÖ´Ù. ²À´ë±âº¸´Ù ¹Ù´Ú ºÎºÐÀÌ ³ÐÀ¸¸ç ²À´ë±â¿¡´Â ¹Ì¼¼ À¶¸ð°¡ Àִµ¥ ±× ¼Ó¿¡´Â ¼¼»ç ´Ù¹ßÀÌ ÇÔÀ¯µÇ¾î ÀÖÀ¸¸ç, ÀÌµé ¼¼»ç ´Ù¹ß »çÀÌ¿¡ ¼¼Æ÷¸·ÀÌ ÇÔÀÔµÈ ¼Ò¿òµéÀÌ ÀÖ´Ù.
  • cell
    ¼¼Æ÷, ¹úÁý, ºÀ¼Ò
    1. »ýü Á¶Á÷ÀÇ ±âº» ´ÜÀ§. Çö¹Ì°æÀ¸·Î °üÂûÀÌ °¡´ÉÇÑ À¯±âü¸¦ ±¸¼ºÇÏ´Â ´Ù¾çÇÑ ¿øÇüÁú µ¢¾î¸® Áß ÇÑ °¡Áö. °¢ ¼¼Æ÷´Â ¼¼Æ÷¸·, ¿øÇüÁú, ÇÙ, ´Ù¾çÇÑ ºÀÀÔü¸¦ °¡Áö°í ÀÖ´Ù. °¢ ¼¼Æ÷ Á¾·ù´Â °¢°¢ÀÇ ´ë»ç ¿ä±¸, ÀÛ¿ë, Åõ°úµµ, ´Ù¸¥ ¼¼Æ÷·Î ºÐÈ­ÇÏ´Â ´É·Â, Àç»ý»ê¼º°ú ¼ö¸íÀ» °¡Áø »ì¾Æ ÀÖ´Â ´ÜÀ§ÀÌ´Ù. 2. »ý¹°ÀÇ ¸öÀ» ±¸¼ºÇÏ´Â ÃÖ¼ÒÀÇ ´ÜÀ§. ¸¹Àº »ý¹°Àº ´Ù¼öÀÇ ¼¼Æ÷·Î ÀÌ·ç¾îÁ® Àֱ⠶§¹®¿¡ ´Ù¼¼Æ÷ »ý¹°À̶ó°í ÇÏÁö¸¸, ¾î¶² Á¾¿¡¼­´Â ±× ÀÚü°¡ ÇϳªÀÇ ¼¼Æ÷·Î µÇ¾î Àֱ⠶§¹®¿¡ ´Ü¼¼Æ÷»ý¹°À̶ó ÇÑ´Ù. ¼¼±Õ, ±ÔÁ¶, ¹Ý´Þ¸», Ŭ·Î·¼¶ó¿Í °°Àº °£´ÜÇÑ Á¶·ù, ¾Æ¸Þ¹Ù, ¤½Å¹ú·¹¿Í °°Àº ¿ø»ýµ¿¹° µîÀº ´Ü¼¼Æ÷»ý¹°ÀÌ´Ù. º¸Åë µ¿¹°ÀÇ ³­ÀÚ´Â ¹ß»ý Ãʱ⿡´Â ´Ü¼¼Æ÷ÀÌÁö¸¸, °ð ºÐ¿­ÇÏ¿© ´Ù¼¼Æ÷·Î µÈ´Ù. ´«À¸·Î º¸ÀÌ´Â °Í¿¡´Â ¹ß»ý ÃʱâÀÇ µ¿¹°ÀÇ ³­ÀÚ, ½Å°æ¼¼Æ÷
  • cell adhesion molecular deficiency
    ¼¼Æ÷ À¯Âø ºÐÀÚ °áÇÌ
  • cell adhesive matrix assay
    ¼¼Æ÷ Á¡Âø ±âÁú ºÐ¼®
  • cell axon terminal
    ¼¼Æ÷ Ãà»è Á¾¸»
  • cell bound antibody
    ¼¼Æ÷ °áÇÕ Ç×ü
    Ç×ü´Â Fc ºÎÀ§¸¦ °³Àç½ÃÄÑ ¼¼Æ÷ÀÇ Fc ¼ö¿ë±â¿Í °áÇÕÇϴµ¥ ÀϹÝÀûÀ¸·Î ´Üüº¸´Ùµµ ÁßÇÕüÀÎ ÆíÀÌ ¼¼Æ÷¿¡ ´ëÇÑ Ä£È­¼ºÀÌ ³ô¾ÆÁø´Ù. ½ÇÁ¦ÀÇ °áÇÕ ´É·ÂÀº ¸é¿ª ±Û·ÎºÎ¸° class »çÀÌ¿¡¼­ ÇöÀúÇÑ Â÷À̸¦ º¸°Ô µÇ´Âµ¥ ¼¼Æ÷°¡ ´Ù¸£¸é °¢°¢¿¡ ´ëÇÑ Ä£È­¼ºÀÌ º¯È­Çϰí Ç×ü¿Í ¼¼Æ÷ ¾çÂÊÀÇ ¼ºÁúÀÌ °ü¿©ÇÏ´Â °ÍÀ¸·Î »ý°¢µÇ¾î ÀÖ´Ù. ´Üü Áß¿¡¼­µµ IgE³ª ¼³Ä¡·ù µ¿¹°ÀÇ IgG´Â µ¿Á¾ ģȭ¼º Ç×ü¶ó°í ºÒ¸®¿ì¸ç ¾Ë·¹¸£±â³ª ¾Æ³ªÇʶô½Ã½º ¹ÝÀÀÀÇ ±âÀÎÀÌ µÈ´Ù.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 19
diabetes, type 2 Non-insulin dependent diabetes, adult-onset diabetes or insulin-resistant diabetes.
(12 Dec 1998)
disease, gaucher's type 1 A progressive genetic disease caused by a defect in an enzyme. The enzyme, called glucocerebrosidase, is needed to break down the chemical glucocerebroside. The enzyme defect in persons with Gaucher's disease (GD) leads to the accumulation of glucocerebroside in the spleen, liver, and lymph nodes. The most common early sign is enlargement of the spleen (located in the upper left abdomen). Other signs include low red blood cell counts (anaemia), a decrease in blood clotting cells (platelets), increased pigmentation of the skin, and a yellow fatty spot on the white of the eye (a pinguecula). Severe bone involvement can lead to pain and collapse of the bone of the hips, shoulders, and spine. The GD gene is on chromosome 1. The disease is a recessive trait. Both parents carry a GD gene and transmit it for their child with the disease. The parents' risk of a child with the disease is 1 in 4 with each pregnancy. This type of Gaucher's disease (noncerebral juvenile Gaucher's disease) is most common in Ashkenazi Jews (of European origin) and is the most common genetic disease among Jews in the United States.
(12 Dec 1998)
immunization, haemophilus influenzae type b See immunization, hib.
(12 Dec 1998)
influenza type a A common acute viral infection of the nasopharynx and respiratory tract which occurs in epidemic forms. A common cause is the Influenza a virus. Annual vaccination is recommended for those in high risk groups (health care workers, elderly and immunocompromised) for influenza infection.
Common symptoms include runny nose, fever, weakness, headache, body aches, muscle aches, nausea and back pain. Treatment of symptoms has been successful with amantadine or rimantadine.
(27 Sep 1997)
interferon type I <chemical> Interferon secreted by leukocytes, fibroblasts, or lymphoblasts in response to viruses or interferon inducers other than mitogens, antigens, or allo-antigens. They include alpha- and beta-interferons (interferon-alpha and interferon-beta).
Pharmacological action: antineoplastic agent, antiviral agents.
(12 Dec 1998)
interferon type II <chemical> The major interferon produced by mitogenically or antigenically stimulated lymphocytes. It is structurally different from type I interferon (interferon type I) and its major activity is immunoregulation. It has been implicated in the expression of class II histocompatibility antigens in cells that do not normally produce them, leading to autoimmune disease.
Pharmacological action: antineoplastic agent, antiviral agents.
Chemical name: Interferon-gamma (human lymphocyte protein moiety reduced)
(12 Dec 1998)
ocean-type fish An anadromous fish that shows no indication on its scales or other hard parts of an extended freshwater residence early in its life.
(09 Oct 1997)
Ellis type 1 glomerulonephritis An obsolete designation for glomerulonephritis presenting as acute glomerulonephritis, followed by complete recovery in most cases, or the development of rapidly progressive glomerulonephritis, or incomplete remission with persistent proteinuria and subsequent development of chronic glomerulonephritis.
Synonym: Ellis type 1 nephritis.
(05 Mar 2000)
Ellis type 1 nephritis An obsolete designation for glomerulonephritis presenting as acute glomerulonephritis, followed by complete recovery in most cases, or the development of rapidly progressive glomerulonephritis, or incomplete remission with persistent proteinuria and subsequent development of chronic glomerulonephritis.
Synonym: Ellis type 1 nephritis.
(05 Mar 2000)
Ellis type 2 glomerulonephritis An obsolete designation for glomerulonephritis which is usually not related to preceding bacterial infection; characterised by an insidious onset of the nephrotic syndrome, failure of complete remission, and eventual development of chronic renal failure. The kidneys usually show membranous glomerulonephritis.
Synonym: Ellis type 2 nephritis.
(05 Mar 2000)
Ellis type 2 nephritis An obsolete designation for glomerulonephritis which is usually not related to preceding bacterial infection; characterised by an insidious onset of the nephrotic syndrome, failure of complete remission, and eventual development of chronic renal failure. The kidneys usually show membranous glomerulonephritis.
Synonym: Ellis type 2 nephritis.
(05 Mar 2000)
Ellis type II <nephrology> A type of nephritis that is characterised by low serum albumin, large amount of protein in the urine and swelling (oedema). Swelling, weight gain, high blood pressure and anorexia are key features. Nephrotic syndrome can be seen with a number of illness that cause damage to the kidney glomerulus.
Examples include diabetes, hereditary disorders, lupus, multiple myeloma, amyloidosis, glomerulonephritis, minimal change disease and membranous glomerulonephritis.
(27 Sep 1997)
erotomanic type of paranoid disorder The false belief that one is loved by another such as a movie star or a casual acquaintance.
(05 Mar 2000)
tuberculin-type hypersensitivity A local or generalised response that begins 24 to 48 hours after exposure to an antigen.
See: cell-mediated reaction.
Synonym: contact hypersensitivity, delayed hypersensitivity, late reaction, tuberculin-type hypersensitivity.
(05 Mar 2000)
jealous type of paranoid disorder The false belief that one's spouse or lover is unfaithful and leading to repeated confrontation, or the taking of extraordinary steps to intervene in the imagined infidelity.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 19
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 19
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 19
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 19
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 19
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 19
ÅëÇÕ°Ë»ö ¿Ï·á